Article PDF
Avoid common mistakes on your manuscript.
References
Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., Borquez-Ojeda, O., Qu, J., Wasielewska, T., He, Q., Bernal, Y., Rijo, I.V., Hedvat, C., Kobos, R., Curran, K., Steinherz, P., Jurcic, J., Rosenblat, T., Maslak, P., Frattini, M., and Sadelain, M. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5, 177ra138.
Dai, H., Zhang, W., Li, X., Han, Q., Guo, Y., Zhang, Y., Wang, Y., Wang, C., Shi, F., Zhang, Y., Chen, M., Feng, K., Wang, Q., Zhu, H., Fu, X., Li, S., and Han, W. (2015). Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology 4, e1027469.
Deng, Z., Wu, Y., Ma, W., Zhang, S., and Zhang, Y.Q. (2015). Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol 16, 1.
Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., Kong, J., Wang, H., Yang, S., Gu, J., and Li, Z. (2014). Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 20, 6418–6428.
Garfall, A.L., Maus, M.V., Hwang, W.T., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Zheng, Z., Vogl, D.T., Cohen, A.D., Weiss, B.M., Dengel, K., Kerr, N.D., Bagg, A., Levine, B.L., June, C.H., and Stadtmauer, E.A. (2015). Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med 373, 1040-1047.
Gross, G., Waks, T., and Eshhar, Z. (1989). Expression of immunoglobulin- T-cell receptor chimeric molecules as functional receptors with antibody- type specificity. Proc Natl Acad Sci USA 86, 10024–10028.
Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., Milone, M.C., Levine, B.L., and June, C.H. (2013). Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. N Engl J Med 368, 1509–1518.
Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F., and Kurosawa, Y. (1987). Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 149, 960-968.
Lamers, C.H.J., Sleijfer, S., Vulto, A.G., Kruit, W.H.J., Kliffen, M., Debets, R., Gratama, J.W., Stoter, G., and Oosterwijk, E. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24, e20–e22.
Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., Steinberg, S.M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S.A., Wayne, A.S., and Mackall, C.L. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528.
Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., and June, C.H. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365, 725-733.
Tang, X., Zhou, Y., Li, W., Tang, Q., Chen, R., Zhu, J., and Feng, Z. (2014). T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo. J Biomed Res 28, 468–475.
Wang, H., Wei, H., Zhang, R., Hou, S., Li, B., Qian, W., Zhang, D., Kou, G., Dai, J., and Guo, Y. (2009). Genetically targeted T cells eradicate established breast cancer in syngeneic mice. Clin Cancer Res 15, 943–950.
Wang, W., Ma, Y., Li, J., Shi, H.S., Wang, L.Q., Guo, F.C., Zhang, J., Li, D., Mo, B.H., Wen, F., Liu, T., Liu, Y.T., Wang, Y.S., and Wei, Y.Q. (2013). Specificity Redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther 20, 970–978.
Zhang, T., Cao, L., Xie, J., Shi, N., Zhang, Z., Luo, Z., Yue, D., Zhang, Z., Wang, L., Han, W., Xu, Z., Chen, H., and Zhang, Y. (2015). Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. Oncotarget 6, 33961–33971.
Zhang, W.Y, Wang, Y., Guo, Y.L., Dai, H.R., Yang, QM., Zhang, Y.J., Zhang, Y., Chen, M.X., Wang, C.M., Feng, K.C., Li, S.X., Liu, Y., Shi, F.X., Luo, C., and Han, W.D. (2016). Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Transduct Targeted Ther 1, 16002. doi:10.1038/ sigtrans.2016.2
Author information
Authors and Affiliations
Corresponding author
Additional information
Biographical Sketch Yu-Quan Wei, a well-known Professor of Oncology. He was born in Nanjiang, Sichuan Province, May 1959. He is a member of the China Academy of Science. He is the Director of the State Key Laboratory of Biotherapy and vice president of Sichuan University. Professor Wei focuses on using biotherapy for diseases, including cancers, autoimmune diseases, and cardiovascular diseases.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Wei, YQ. Armed T cells with CAR for cancer immunotherapy. Sci. China Life Sci. 59, 331–332 (2016). https://doi.org/10.1007/s11427-016-5047-0
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-016-5047-0